AMGEN TO PRESENT INNOVATIVE RHEUMATOLOGY RESEARCH AT EULAR 2024
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- Wall Street ends lower, off record highs, as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- Sportradar to sell Synergy Sports coaching unit for $170M
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
- Wall Street ends lower, off record highs, as Treasury yields climb
- Applied Digital (APLD) Tops Q1 EPS by 26c, Beats on Revenue
Amgen (AMGN) PT Raised to $332 at RBC Capital
June 14, 2024 6:15 AM EDTRBC Capital analyst Gregory Renza raised the price target on Amgen (NASDAQ: AMGN) to $332.00 (from $328.00) while maintaining a Outperform rating.
The analyst comments "2024 sentiment on AMGN remains tethered to obesity program, MariTide, a GLP-1R agonist/ GIPR antagonist, very encouraging ph.II... More



